Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 9 of 12, showing 5 Applications out of 57 total, starting on record 41, ending on 45

# Protocol No Study Title Investigator(s) & Site(s)

41.

ECCT/16/02/01   ASSESSING THE ACCURACY, USABILITY AND ACCEPTABILITY OF CHILDREN’S AUTOMATED RESPIRATORY MONITOR AT SELECTED CLINICS IN TURKANA COUNTY, KENYA ‘
            ASSESSING THE ACCURACY, USABILITY AND ACCEPTABILITY OF CHILDREN’S AUTOMATED RESPIRATORY MONITOR AT SELECTED CLINICS IN  TURKANA COUNTY, KENYA ‘         
Principal Investigator(s)
1. ISAIAH MWANGI
Site(s) in Kenya
1. lodwar hospital (Turkana county)
 
View

42.

ECCT/15/11/04   VAC040
    A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months)   
Principal Investigator(s)
1. John Anthony Gerard Scott
Site(s) in Kenya
KEMRI-Wellcome Trust Research Program
 
View

43.

ECCT/15/10/01   VRC01 Monoclonal HIV Antibodies Study
    Safety  and  Virologic Effect  Of  A  Human   Monoclonal   Antibody,   VRC-HIVmAb060-00-Ab  (VRCOl),   With Broad  HIV-1  Neutralizing Activity, Administered Intravenously to Adults  During Early Acute HIV Infection.   
Principal Investigator(s)
1. Josphat K Kosgei
Site(s) in Kenya
KEMRI Walter Reed Project Kericho
 
View

44.

ECCT/15/04/02  
    Plasma concentration profiles after oral  administration of oleylphosphocholine tablet  formulation: safety, tolerability and pharmacokinetics  of 100 mg single dose in healthy male volunteers.   
Principal Investigator(s)
1. Ravasco Rashid Juma
Site(s) in Kenya
KEMRI
 
View

45.

ECCT/14/11/02   A5297
    An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and < 500 cells/mm3   
Principal Investigator(s)
1. VICTOR AKELO
Site(s) in Kenya
KEMRI/CDC CLINICAL RESEARCH CENTRE
 
View